Common Contracts
4 similar Purchase Agreement contracts by Aptevo Therapeutics Inc., Magnegas Corp, Sophiris Bio Inc., Venaxis, Inc.
Aptevo Therapeutics Inc. Common Stock and Warrants to Purchase Common Stock PURCHASE AGREEMENTPurchase Agreement • March 11th, 2019 • Aptevo Therapeutics Inc. • Pharmaceutical preparations • New York
Aptevo Therapeutics Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of (i) 19,850,000 shares (the “Shares”) of Common Stock, $0.001 par value per share (the “Common Stock”), of the Company, (ii) warrants to purchase up to 22,000,000 shares of Common Stock in the form set forth on Exhibit A (the “Warrants”) and (iii) pre-funded warrants to purchase up to 2,150,000 shares of Common Stock at an exercise price of $0.01 per share in the form set forth on Exhibit B (the “Pre-Funded Warrants” and, together with the Shares and the Warrants, the “Securities”) Each Share is being sold together with a Warrant to purchase one (1) share of Common Stock at an exercise price of $1.30 per whole share of Common Stock. Each Pre-Funded Warrant is being sold with a Warrant to purchase one (1) share of Common Stock at an exercise price of $1.30 per whole share of Common Stock. The shares of Com
6,500,000 Common Shares and Warrants to Purchase 4,875,000 Common Shares SOPHIRIS BIO INC. PURCHASE AGREEMENTPurchase Agreement • August 23rd, 2016 • Sophiris Bio Inc. • Pharmaceutical preparations • New York
Sophiris Bio Inc., a British Colombia corporation (and together with its subsidiaries, the “Company”) proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of (i) 6,500,000 shares (the “Firm Shares”) of Common Shares, no par value per share (the “Common Shares”), of the Company and (ii) warrants to purchase up to 4,875,000 Common Shares in the form set forth in Exhibit A (each, a “Warrant”). Each Firm Share is being sold together with a Warrant to purchase 0.75 Common Shares at an exercise price of $4.00 per whole Common Share. The Company has also granted to the Underwriters an option to purchase up to 975,000 additional Common Shares (“Option Shares”) with additional Warrants to purchase up to 731,250 Common Shares (“Option Warrants”), on the terms and for the purposes set forth in Section 3 hereof. The Firm Shares, Option Shares, Warrants and Option Warrants are collectively called the “Securities.” The Common Shares underlying the
and Warrants to Purchase [l] Shares of Common Stock MagneGas Corporation PURCHASE AGREEMENTPurchase Agreement • May 31st, 2013 • Magnegas Corp • Special industry machinery, nec • New York
Ÿ ] Shares of Common Stock1 and Warrants to Purchase [ Ÿ ] Shares of Common Stock Venaxis, Inc. PURCHASE AGREEMENTPurchase Agreement • May 23rd, 2013 • Venaxis, Inc. • In vitro & in vivo diagnostic substances • New York
